| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 538,407 | 563,864 | ||
| Prepayments and other receivables | 28,074 | 30,688 | ||
| Marketable securities, current | 164,539 | 175,298 | ||
| Restricted cash | 1,308 | - | ||
| Total current assets | 732,328 | 769,850 | ||
| Marketable securities, net of current portion | 53,091 | 44,172 | ||
| Property, plant and equipment, net | 323 | 312 | ||
| Operating right of use asset | 246 | 308 | ||
| Intangible assets | 439 | 470 | ||
| Total assets | 786,427 | 815,112 | ||
| Accounts payable | 3,632 | 5,895 | ||
| Accrued expenses and other current liabilities | 10,098 | 9,460 | ||
| Lease liability, current | 181 | 225 | ||
| Derivative warrant liabilities | 44,361 | 20,932 | ||
| Total current liabilities | 58,272 | 36,512 | ||
| Lease liability, net of current portion | 85 | 103 | ||
| Total liabilities | 58,357 | 36,615 | ||
| Ordinary shares | 14,107 | 14,014 | ||
| Additional paid-in capital | 1,396,790 | 1,375,618 | ||
| Accumulated loss | -687,467 | -615,462 | ||
| Accumulated other comprehensive income | 4,640 | 4,327 | ||
| Total shareholders' equity | 728,070 | 778,497 | ||
| Total liabilities and shareholders' equity | 786,427 | 815,112 | ||
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)